Mansfield, United States
Biorasis Inc., founded in December 2007, is at the forefront of developing cutting-edge, real-time, wireless sensor technology designed for continuous glucose and bio-analyte monitoring. With its origins in research at UCONN and OSCI, the company has developed a miniaturized sensor platform that is revolutionizing healthcare by enabling accurate monitoring of medical conditions. The device, which measures just 0.5 x 0.5 x 5 mm, stands out for its innovative approach by being needle-implantable and wirelessly operatable.
Originally focused on glucose monitoring, Biorasis is strategically expanding its capabilities to track other critical bio-analytes, potentially impacting treatment and management of cardiovascular diseases, cancer, liver and kidney issues, stroke, and epilepsy.
In terms of investment, Biorasis secured a $3.00M grant from The Leona M. and Harry B. Helmsley Charitable Trust on 01 December 2018. Headquartered in the United States, the company is positioned in the intersection of Biotechnology, Health Care, IT, and Internet, promising substantial advancements in healthcare monitoring technologies.
